<?xml version='1.0' encoding='utf-8'?>
<document id="8846623"><sentence text="Managing selective serotonin reuptake inhibitor-drug interactions in clinical practice."><entity charOffset="19-28" id="DDI-PubMed.8846623.s1.e0" text="serotonin" /></sentence><sentence text="Combination drug therapy is common in psychiatry" /><sentence text=" It plays a role in the treatment of patients with multiple disorders, in the management of residual symptoms or resistant disease, and in the alleviation of unwanted effects of the primary drug" /><sentence text=" Coadministration of psychotropic drugs with medications for medical illnesses is becoming more common as well, because as many as half the patients with major depression require long term treatment, and because the number of patients who are elderly is increasing as the population ages" /><sentence text=" To safely manage multidrug regimens, the clinician must be knowledgeable about drug-drug interaction potential" /><sentence text=" Drug-drug interactions can produce a change in the pharmacological effect of a drug by altering activity at the site of action (a pharmacodynamic interaction), or by changing the plasma concentrations of a drug (a pharmacokinetic interaction), or both" /><sentence text=" Selective serotonin reuptake inhibitors (SSRIs) have the potential to impair the oxidative metabolism of several drugs, including tricyclic antidepressants and neuroleptics"><entity charOffset="11-20" id="DDI-PubMed.8846623.s7.e0" text="serotonin" /></sentence><sentence text=" However, the SSRIs highlight the maxim that overgeneralisation can be as detrimental to rational co-pharmacy as ignorance of interaction potential" /><sentence text=" The SSRIs differ in terms of which other drugs they affect, which patients are at risk, and to what extent the effect is clinically important" /><sentence text=" Clinicians must assess drug combinations on a case-by-case basis" /><sentence text=" Standard management practices of dose titration, monitoring plasma drug concentrations when the therapeutic index is narrow, and observing for adverse events minimise the clinical impact of potential drug-drug interactions" /><sentence text="" /></document>